Competing Causes of Death and Second Primary Tumors in Patients with Locoregionally Advanced Head and Neck Cancer Treated with Chemoradiotherapy

Clinical Cancer Research

Volumn 10, Issue 6, 2004, Pages 1956-1962

  Argiris, Athanassios ^a   Brockstein, Bruce E ^a,c   Haraf, Daniel J ^b   Stenson, Kerstin M ^b   Mittal, Bharat B ^a   Kies, Merrill S ^a,e   Rosen, Fred R ^d   Jovanovic, Borko ^a   Vokes, Everett E ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b University of Chicago   (United States)

^c EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; COMORBIDITY; ESOPHAGUS CANCER; FEMALE; HEAD AND NECK CANCER; HEART DISEASE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPIRATORY TRACT DISEASE; SECOND CANCER; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; COMORBIDITY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 1642382955     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-1077     Document Type: Article

References (40)

1. Vokes EE, Weichselbaum RR, Lippman S, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-94.
2. Jacobs C. The internist in the management of head and neck cancer. Ann Intern Med 1990;113:771-8.
3. Lippman SM, Hong WK. Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 1989;17:691-4.
4. Hall SF, Groome PA, Rothwell D. The impact of comorbidity on the survival of patients with squamous cell carcinoma of the head and neck. Head Neck 2000;22:317-22.
5. Skarsgard DP, Groome PA, Mackillop WJ, et al. Cancers of the upper aerodigestive tract in Ontario, Canada, and the United States. Cancer 2000;88:1728-38.
6. Vokes EE, Stenson K, Rosen FR, et al. Weekly Carboplatin and Paclitaxel followed by concomitant Paclitaxel, Fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003;21:320-6.
7. Adelstein DJ, Saxton JP, Lavertu P, et al. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol 2002;20:1405-10.
8. Rosen FR, Haraf D, Kies MS, et al. Multicenter randomized phase II study of paclitaxel (1 hour infusion), fluorouracil, hydroxyurea and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res 2003;6:1689-97.
9. Vokes EE, Kies MS, Haraf DJ, et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000;18:1652-61.
10. Kies MS, Haraf DJ, Rosen F, et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 2001;19:1961-9.
11. Shin DM, Glisson BS, Khuri FR, et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 2002;95:322-30.
12. Vokes EE, Kies M, Haraf DJ, et al. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease. J Clin Oncol 1995;13:876-83.
13. Kies MS, Haraf DJ, Athanasiadis I, et al. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol 1998;16:2715-21.
14. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early- stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002;20:2101-8.
15. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21:1513-23.
16. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002;20:3484-94.
17. Fish EB, Chapman JA, Link MA. Competing causes of death for primary breast cancer. Ann Surg Oncol 1998;5:368-75.
18. Slaughter DP, Southwick HW, Smejkal W. "Filed cancerization" in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953;6:963-8.
19. Brockstein BE, Haraf DJ, Kies MS, et al. Survival, patterns of failure, and risk factors for recurrence after intensive concomitant chemoradiation (CRT) for squamous cell head and neck cancer (SCHNC). Proc Am Soc Clin Oncol 2002;21:A918.
20. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Statis Assoc 1958;53:457-81.
21. Tai BC, Machin D, White I, Gebski V. Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches. Stat Med 2001;20:661-84.
22. Klein JP. Survival analysis methods in cancer studies. Cancer Treat Res 2002;113:37-57.
23. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant 2001;28:909-15.
24. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 1993;12:737-51.
25. Pepe MS, Longton G, Pettinger M, Mori M, Fisher LD, Storb R. Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: motivation for and description of new methods. Br J Haematol 1993;83:602-7.
26. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706.
27. Jones AS, Morar P, Phillips DE, Field JK, Husband D, Helliwell TR. Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer 1995;75:1343-53.
28. Cooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989;17:449-56.
29. Erkal HS, Mendenhall WM, Amdur RJ, Villaret DB, Stringer SP. Synchronous and metachronous squamous cell carcinomas of the head and neck mucosal sites. J Clin Oncol 2001;19:1358-62.
30. Fijuth J, Mazeron JJ, Le Pechoux C, et al. Second head and neck cancers following radiation therapy of T1 and T2 cancers of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 1992;24:59-64.
31. Roberts TJ, Epstein B, Lee DJ. Second neoplasms in patients with carcinomas of the vocal cord: incidence and implications for survival. Int J Radiat Oncol Biol Phys 1991;21:583-9.
32. Schwartz LH, Ozsahin M, Zhang GN, et al. Synchronous and metachronous head and neck carcinomas. Cancer 1994;74:1933-8.
33. Leon X, Ferlito A, Myer CM, 3rd, et al. Second primary tumors in head and neck cancer patients. Acta Otolaryngol 2002;122:765-78.
34. Khuri FR, Kim ES, Lee JJ, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomark Prev 2001;10:823-9.
35. Cianfriglia F, Di Gregorio DA, Manieri A. Multiple primary tumours in patients with oral squamous cell carcinoma. Oral Oncol 1999;35:157-63.
36. Moore C. Cigarette smoking and cancer of the mouth, pharynx, and larynx. A continuing study. JAMA 1971;218:553-8.
37. Pinto H, Li Y, Loprinzi C, Kardinal C, Adams G, Pandya K. Phase III trial of low-dose 13-cis-retinoic acid for prevention of second primary cancers in stage I-II head and neck cancer- an Eastern Cooperative Oncology Group Study. Proc Am Soc Clin Oncol 2001;20:A886.
38. Argiris A, Smith SM, Stenson K, et al. Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary. Ann Oncol 2003;14:1306-11.
39. Shin DM, Khuri FR, Murphy B, et al. Combined interferon-α, 13-cis-retinoic acid, and α-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001;19:3010-7.
40. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.